Company: CERO
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001213900-25-079898
Chunk: 204

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 8
Chunk 204
---
 Series D Preferred Stock for gross cash proceeds of $432,600 in an additional closing of the Fourth PIPE
Financing.

July
2025 ELOC Transaction

On
July 11, 2025, the Company entered into an agreement to issue and sell 12,500,000 shares of Common Stock under the New Keystone Purchase
Agreement. As the New Keystone Purchase Agreement constitutes a continuation of the equity line program commenced under the February
2024 Purchase Agreement, the Commitment Shares issued to the Investor pursuant to the February 2024 Purchase Agreement shall satisfy
in full the Company’s obligation to deliver any additional shares of Common Stock to the Investor as consideration for entering into
the New Keystone Purchase Agreement.

Orphan Drug Designation

In
July 2025, CER-1236 received an FDA Orphan Drug Designation for the treatment of acute myeloid leukemia.

Nasdaq
Notices of Non-compliance and Nasdaq Panel Decision

As
previously disclosed, on January 17, 2025, the Company received a letter setting forth the determination of a panel convened by Nasdaq
(the “Nasdaq Panel”) granting the Company’s request for an extension (the “Extension”) to regain compliance
with certain continued listing requirements of the Nasdaq Stock Market until April 22, 2025. The Company presented its plan (the “Plan”)
for regaining compliance with such requirements at a hearing conducted on December 17, 2025. The Company’s Plan included completion
of a reverse stock split, which occurred on January 8, 2025, and transferring the listing of its securities to the Nasdaq Capital Market,
which was completed on February 12, 2025, and certain other conditions, including the satisfaction of the $2.5 million minimum stockholders’
equity requirement for continued listing on the Nasdaq Capital Market.

In addition, as previously disclosed, from November 2024 through June
30, 2025, the Company raised approximately $3.1 million of net proceeds from its equity line of credit entered into November 2024, and
an additional approximately $4.3 million of net proceeds from its public offering of shares of common stock, pre-funded warrants and warrants
to purchase shares of common stock that closed on February 7, 2025 (the “February 2025 Offering”). As a result of such capital
raising activities and the proceeds of the Private Placement received on the First Closing Date, as well